---
title: "NCPC: Restructured Tetanus Vaccine (Escherichia coli) Clinical Trial Approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240320337.md"
description: "According to the Zhitong Finance APP, NCPC announced that its subsidiary, North China Pharmaceutical Jintan Biotechnology Co., Ltd. (referred to as \"Jintan Company\"), has received the \"Drug Clinical Trial Approval Notice\" for the recombinant tetanus vaccine (Escherichia coli) approved by the National Medical Products Administration"
datetime: "2025-05-15T08:28:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240320337.md)
  - [en](https://longbridge.com/en/news/240320337.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240320337.md)
generator: "portal-rs"
---

# NCPC: Restructured Tetanus Vaccine (Escherichia coli) Clinical Trial Approved

According to the Zhitong Finance APP, NCPC (600812.SH) announced that its subsidiary, North China Pharmaceutical Jintan Biotechnology Co., Ltd. (referred to as "Jintan Company"), has received the "Drug Clinical Trial Approval Notice" for the recombinant tetanus vaccine (Escherichia coli) approved by the National Medical Products Administration

### Related Stocks

- [600812.CN](https://longbridge.com/en/quote/600812.CN.md)

## Related News & Research

- [China CITIC Bank Unveils 2026 Interim Results and RMB11.3 Billion Dividend Plan](https://longbridge.com/en/news/297047386.md)
- [SP Group corrects disclosure, names Schur Finance as buyer of 31,500 shares at DKK 485](https://longbridge.com/en/news/296803384.md)
- [08:44 ETNew Ownership of Parcel Plus in Houston, Texas Continues 12-Year Legacy Serving the Community with Shipping and Office Services](https://longbridge.com/en/news/297047704.md)
- [Four Seasons Hotel Washington, DC hosts Wine & Dine fundraiser for MedStar Health lung cancer research](https://longbridge.com/en/news/296948001.md)
- [Polska Grupa Hutnicza discloses related-party share transaction under MAR rules](https://longbridge.com/en/news/296917492.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**